Abstract
Introduction

Since its molecular identification, the adult central nervous system (CNS) myelin-associated Nogo
has been intensively investigated pertaining to its role in inhibiting CNS neuronal regeneration [4] [5] [6] [7] . flanked by two hydrophobic segments, is characteristic of the RTN family of proteins [8] . [9, 10] . These include the N-terminal region encoded by exon 3, and the extracellular Nogo-66 segment. Nogo-66 binds to an axonal Nogo-66 receptor (NgR) [9] . The [11] [12] [13] . A segment within the exon 3- A [51] . Although the earlier study [46] showed that Nogo-A was not elevated in experimental muscle denervation, another report has detailed contradicting observations with the analysis of both Nogo-A transcripts and proteins [56] . These other reported observations may have weakened Nogo-A's potential as an ALS-specific marker [51, 57] , and the merit of Nogo-A's diagnostic/prognostic value in ALS awaits further confirmation with larger clinical cohorts. 
. The Nogo/reticulon (RTN)-4 gene has several splice isoforms, the major ones being Nogo-A, B and C. The longest of these, Nogo-A/RTN-4A, is enriched in the brain and spinal cord
Nogo-B/RTN4B is found in the brain, but unlike Nogo-A, has a more ubiquitous expression pattern. Nogo-C/RTN-4C is particularly enriched in the muscle. The Nogo splice isoforms have N-terminal domains of varying length, but they share an identical C-terminal domain. This C-terminal domain, consisting of a 66-amino acid sequence
Molecular dissection of Nogo-A has revealed three separate regions that have neurite growth inhibitory activity
latter, a glycosylphosphatidylinositol (GPI)-linked molecule with leucine-rich repeats, also functions as a receptor for two other myelin-associated inhibitors, the myelinassociated glycoprotein (MAG) and the oligodendrocyte myelin glycoprotein (OMgp)
encoded domain found at the N-terminus of Nogo-A also has a high affinity for NgR [14], and this could form a bipartite interaction with NgR, together with the Nogo-66 domain. Intriguingly, this segment could modulate the mode of binding of Nogo-66-derived peptides with NgR, effectively changing the downstream effect of the peptide ligand-receptor association. It is unclear if there exist other specific neuronal receptors for this exon 3-encoded domain of Nogo-A, but recent findings revealed that the N-terminal portion of Nogo-A acts through inhibition of the integrin signalling [15]. The very N-terminus of Nogo-A/B that is shared by both isoforms has also been associated with a vascular
further study by the authors on ALS patients indicated that Nogo-A and Nogo-B expression was significantly correlated with the disease severity measured by the ALS functional rating scale [52]. Nogo-A expression correlated, in particular, with the atrophy of the slow-twitch type 1 fibres, and almost all Nogo-A-positive fibres of this type appeared atrophic. These findings suggest that Nogo-A may be a useful marker to monitor ALS disease progression. A more recent study by the same authors appeared to have strengthened this notion. A proportion of individuals with lower motor neuron syndrome (LMNS), characterized by the presence of lower motor neuron signs (muscle weakness and atrophy with electromyographic abnormalities) but the absence of upper motor neuron signs, progressed to typical ALS. In a 1-year follow-up study, detection of Nogo-A in the muscle biopsy samples from LMNS patients identified the progression to ALS with a 91% accuracy, a 94% sensitivity and an 88% specificity [49]. Nogo-A may be detected as early as 3 months after the onset of LMNS symptoms for patients who eventually developed ALS. The muscle Nogo-A, therefore, has promising diagnostic and prognostic values. The above view has recently been challenged by other workers. Wojcik and colleagues reported that the muscle biopsies from patients with other forms of myopathy and peripheral neuropathies also exhibited elevated Nogo-A immunoreactivity within the denervated muscle fibers
Pathological roles of Nogo-A in ALS
Although it is not yet shown if the administration of these peptides prolongs the motor neuron survival or general lifespan in ALS transgenic mice models, the findings outlined above are interesting and noteworthy in several aspects. First of all, NgR engagement by Nogo-66-derived peptides did not result in a general antiapoptotic signalling, but rather in specifically countering p75 NTRmediated deaths. Apparently, it does not matter if the NgR is bound by an agonist or an antagonist. In other words, whether downstream signalling that leads to growth cone collapse as well as neurite growth inhibition was activated may be irrelevant in this case. What may be necessary is for the ligand-bound NgR to engage p75
NTR in a manner that precludes its apoptotic signalling. [71] . [72] , and recent studies suggest that it is required only for the acute growth cone collapsing of some neurons, but not for the chronic growth inhibitory actions of myelin inhibitors [73] . The
p75 NTR has multiple binding partners [65-67], and it is known that its formation of a receptor complex with sortilin mediates the apoptotic activity of the pro-forms of NGF and BDNF [68, 69]. It is possible that p75 NTR 's interaction with the ligand-bound NgR binding could preclude or displace its interaction with sortilin. This notion is augmented by an interesting aspect of NgR signalling that has emerged recently -it is modulated by cell surface proteolytic processing of itself and its co-receptor. The ligand binding to the cerebellar neurons induces ␣-and ␥-secretasemediated proteolytic cleavage of p75 NTR in a protein kinase C (PKC)-dependent manner [70]. The TNF-␣ converting enzyme (TACE)/a disintegrin and metalloprotease 17 (ADAM17) cleaves NgR and initiates intramembranous cleavage of p75 NTR . In cultured dorsal root ganglion (DRG) neurons, this cleavage could underlie the attenuating effect of neurotrophic factors such as fibroblast growth factor 2 (FGF2) on the axonal growth inhibited by CNS myelin-associated inhibitors
This notion needs further experimental verification (in particular, whether Nogo-B overexpression in the muscles has an effect that is opposite to Nogo-A). It should be noted that the targeted disruption of NgR did not enhance the spinal cord neuron regeneration in some models
Nogo-66-NgR axis may, therefore, not play a critical role in the destabilization of NMJ, and Nogo-66 may well function in a manner that is independent of NgR. The Nogo-A-NgR interaction on the motor neurons can also potentially be a complicated affair. The motor neurons themselves expressed significant amounts of Nogo-A [74], and these may engage the NgRs of the neighbouring neurons. As mentioned earlier, the Nogo-A-specific exon 3-encoded portion contains a domain that also binds NgR with nanomolar affinity and may interact with NgR in conjunction with Nogo-66 [14]. It is unclear at the moment if Nogo-A present in cis form with NgR on axons, or synapses, affects the latter's interaction in trans form with ligands from an opposing cell. It is also unclear as to how neuronal Nogo-A affects the interaction of NgR with its other ligands.
Nogo and NgR as therapeutic targets for ALS?
Although Nogo-A's validity as a biomarker for ALS diagnosis/prognosis may need further confirmation, the above findings suggest Nogo and NgR could be potential targets for ALS adjunct therapy. This may be helped by the fact that the targeted deletion of both Nogo-A [58] [59] [60] and NgR [72, 75] 
